Assessment of quality of life in oral cancer

Quality of life (QL) in oral cancer patients has become one of the most important parameters to consider in the diagnosis and post-treatment follow-up. The purpose of this article has been to review the papers published that study the QL in oral cancer patients, the different QL questionnaires used, the clinical results obtained, and the systematic revisions available in the indexed literature for the last 10 years. The term QL appears as a keyword in an increasing number of articles throughout the past 10 years; however, few studies focus on oral cancer. Most of them assess all head and neck cancers, which conform to a heterogeneous group with several different features depending on location (oral cavity, oropharynx, larynx, hypopharynx, nasopharynx and salivary glands). Most studies evaluate QL in short periods of time, normally within the first year after the diagnosis. Series do not discern between different therapeutic options, and they generally center on Northern European or Northern American populations. There are few instruments translated and validated into Spanish that measure QL, a fundamental characteristic to link QL to own patients? socio-cultural parameters. Data related with QL are mostly related to patient (age, sex, co-morbidity), tumour (location, size), and treatment (surgical treatment, radiotherapy association, reconstruction, cervical dissection, and/or feeding tube). Nowadays QL?s assessment is considered an essential component of an oral cancer patient as well as the survival, morbidity and years free of disease. Although many aspects related to QL in oral cancer patients have been published throughout the past 10 years, more systematic research is needed to be able to apply it on a daily basis

Ectopic third molar in the mandibular condyle: a review of the literature

Objectives: To evaluate the etiopathogenesis, clinical features, therapeutic options, and surgical approaches for removal of ectopic third molars in the mandibular condyle. Study design: MEDLINE search of articles published on ectopic third molars in the mandibular condyle from 1980 to 2011. 14 well-documented clinical cases from the literature were evaluated together with a new clinical case provided by the authors, representing a sample of 15 patients. Results: We found a mean age at diagnosis of 48.6 years and a higher prevalence in women. In 14 patients, associated radiolucent lesions were diagnosed on radiographic studies and confirmed histopathologically as odontogenic cysts. Clinical symptoms were pain and swelling in the jaw or preauricular region, trismus, difficulty chewing, cutaneous fistula and temporomandibular joint dysfunction. Treatment included conservative management in one case and in the other cases, surgical removal by intra- or extraoral approaches, the latter being the most common approach carried out. In most reported cases, serious complications were not outlined. Conclusions: The etiopathogenic theory involving odontogenic cysts in the displacement of third molars to the mandibular condyle seems to be the most relevant. They must be removed if they cause symptoms or are associated with cystic pathology. The surgical route must be planned according to the location and position of the ectopic third molar, and the possible morbidity associated with surgery

Kissing molars extraction: case series and review of the literature

Kissing molars are a very rare form of inclusion defined as molars included in the same quadrant, with occlusal surfaces contacting each other within a single dental follicle. We present four cases of this pathology: a 35 year-old male, referred to the Oral and Maxillofacial Surgery Department of the Hospital Virgen del Rocio in Seville, and three females of 24, 26, and 31 years, all of which had kissing molars that were treated by tooth extraction. We have found only 10 cases published in the medical literature in which this type of inclusion is briefly described, none of which elaborate on the surgical technique employed. In these cases, the indication for surgery is established when there is a history of recurring infections or cystic lesions associated with dental inclusions. The extraction of kissing molars requires an exhaustive comprehension of the anatomy of the region involved, sufficiently developed surgical abilities, and an extensive planning proces

Impact of the coronavirus pandemic on maxillofacial trauma:a retrospective study in southern Spain

The coronavirus pandemic has impacted health systems worldwide, with Spain being one of the most affected countries. However, little is known about the extent to which the effects of staying home, social distancing, and quarantine measures have influenced the epidemiology of patients with maxillofacial trauma. The aim of this study was to analyze the impact of the coronavirus pandemic on the incidence, demographic patterns, and characteristics of maxillofacial fractures in the largest hospital in southern Spain. Data from patients who underwent surgery for maxillofacial fractures during the first year of the pandemic between 16 March 2020 and 14 March 2021 (pandemic group) were retrospectively compared with a control group during the equivalent period of the previous year (pre-pandemic group). The incidence was compared by weeks and by lockdown periods of the population. Demographic information, aetioloy, fracture characteristics, treatment performed, and days of preoperative stay were evaluated. Descriptive and bivariate statistics were calculated (p<0.05). During the first year of the pandemic, there was a 35.2% reduction in maxillofacial fractures (n=59) compared to the pre-pandemic year (n=91, p=0.040). A significant drop was detected during the total home lockdown period of the population (p=0.028). In the pandemic group, there was a reduction in fractures due to interpersonal aggressions, an increase in panfacial fractures, a significant increase in other non-facial injuries associated with polytrauma (p=0.037), a higher number of open reduction procedures with internal fixation, and a significantly longer mean preoperative stay (p=0.016). The first pandemic year was associated with a decline in the frequency of maxillofacial trauma and a change in the pattern and characteristics of fractures. Inter-annual epidemiological knowledge of maxillofacial fractures may be useful for more efficient planning of resource allocation and surgical practice strategy during future coronavirus outbreaks and population lockdowns

Expression of USP18 and IL2RA is increased in individuals receiving latent tuberculosis treatment with isoniazid

Background. The treatment of latent tuberculosis infection (LTBI) in individuals at risk of reactivation is essential for tuberculosis control. However, blood biomarkers associated with LTBI treatment have not been identified. Methods. Blood samples from tuberculin skin test (TST) reactive individuals were collected before and after one and six months of isoniazid (INH) therapy. Peripheral mononuclear cells (PBMC) were isolated, and an in-house interferon-γ release assay (IGRA) was performed. Expression of chemokine ligand 4 (CCL4), chemokine ligand 10 (CXCL10), chemokine ligand 11 (CXCL11), interferon alpha (IFNA), radical S-adenosyl methionine domain-containing 2 (RSAD2), ubiquitin-specific peptidase 18 (USP18), interferon-induced protein 44 (IFI44), interferon-induced protein 44 like (IFI44L), interferon-induced protein tetratricopeptide repeats 1(IFIT1), and interleukin 2 receptor subunit alpha (IL2RA) mRNA levels were assessed by qPCR before, during, and after INH treatment. Results. We observed significantly lower relative abundances of USP18, IFI44L, IFNA, and IL2RA transcripts in PBMC from IGRA-positive individuals compared to levels in IGRA-negative individuals before INH therapy. Also, relative abundance of CXCL11 was significantly lower in IGRA-positive than in IGRA-negative individuals before and after one month of INH therapy. However, the relative abundance of CCL4, CXCL10, and CXCL11 mRNA was significantly decreased and that of IL2RA and USP18 significantly increased after INH therapy, regardless of the IGRA result. Our results show that USP18, IFI44L, IFIT1, and IL2RA relative abundances increased significantly, meanwhile the relative abundance of CCL4, CXCL11, and IFNA decreased significantly after six months of INH therapy in TST-positive individuals. Conclusions. Changes in the profiles of USP18, IL2RA, IFNA, CCL4, and CXCL11 expressions during INH treatment in TST-positive individuals, regardless of IGRA status, are potential tools for monitoring latent tuberculosis treatment

Efecto del clorhidrato de clembuterol en la ganancia de peso y lesiones histológicas en ratones

El clorhidrato de clembuterol (CCL) es un b-agonista promotor del crecimiento en animales para abasto, pero su uso ilícito ha generado repercusiones en salud pública. Se realizó un modelo biológico con ratones, con el objeto de evaluar el efecto del CCL sobre la ganancia de peso y las lesiones histológicas que ocasiona. Los ratones fueron alimentados con carne de conejo, que previamente fue suplementada con CCL. Treinta y cinco días posexposición se registró el peso corporal se obtuvo la concentración muscular y sérica de CCL a través de la prueba de ELISA, y se colectaron tejidos (hígado y corazón) para análisis histopatológico. Los valores obtenidos de los animales experimentales (G1 y G2) se analizaron mediante un diseño experimental completamente al azar con dos tratamientos (n = 10), sometidos a un análisis de varianza y comparación de medias con la prueba de Tukey (p \u3c 05). Se registró un incremento de peso corporal de 7 g en el G1, contra 4,0 g del G2. El peso del hígado fue de 2,58 g y 1,79, respectivamente (p \u3c 05). En el G1 la concentración muscular de CCL fue 5324 pg g–1 y en suero sanguíneo de 4378 pg g–1. Solo se observaron cambios histológicos en tejidos de los ratones del G1. El hígado mostró tumefacción celular, mitosis moderada, picnosis y degeneración hidrópica en corazón, engrosamiento de fibras, pleomorfismo e hileración nuclear. El CCL favoreció el incremento de peso en los ratones expuestos, y provocó alteraciones estructurales en hígado y corazón

Bridging the Gap Between National and Ecosystem Accounting Application in Andalusian Forests, Spain

National accounting either ignores or fails to give due values to the ecosystem services, products, incomes and environmental assets of a country. To overcome these shortcomings, we apply spatially-explicit extended accounts that incorporate a novel environmental income indicator, which we test in the forests of Andalusia (Spain). Extended accounts incorporate nine farmer activities (timber, cork, firewood, nuts, livestock grazing, conservation forestry, hunting, residential services and private amenity) and seven government activities (fire services, free access recreation, free access mushroom, carbon, landscape conservation, threatened biodiversity and water yield). To make sure the valuation remains consistent with standard accounts, we simulate exchange values for non-market final forest product consumption in order to measure individual ecosystem services and environmental income indicators. Manufactured capital and environmental assets are also integrated. When comparing extended to standard accounts, our results are 3.6 times higher for gross value added. These differences are explained primarily by the omission in the standard accounts of carbon activities and undervaluation of private amenity, free access recreation, landscape and threatened biodiversity ecosystem services. Extended accounts measure a value of Andalusian forest ecosystem services 5.4 times higher than that measured using the valuation criteria of standard accounts

Serum pro-inflammatory biomarkers associated with improvement in quality of life in pulmonary tuberculosis

IntroductionPulmonary dysfunction is an underestimated complication in tuberculosis (TB) infection, affecting quality of life (QoL). Although respiratory function tests objectively reflect lung disturbances in a specific moment, predictors of illness severity at the time of diagnosis are still lacking.MethodsWe measured serum pro-inflammatory cytokines (TNF-α and IL-8), eicosanoids (PGE2, LTB4, RvD1, Mar1, and LXA4), a marker of tissue damage (cell-free nucleosomes), and indicators of redox status (malonaldehyde, 8-isoprostane, total oxidants, and antioxidants), as well as a score of radiological abnormalities (SRA) and a QoL questionnaire, in 25 patients with pulmonary TB at the time of diagnosis (t0) and two months after the initiation of treatment (t2).ResultsWe found higher antioxidant levels in the patients with the worst QoL at t0, and all the indicators of the prooxidant state were significantly reduced at t2, while the total antioxidant levels increased. LTB4, a pro-inflammatory eicosanoid, was diminished at t2, while all the pro-resolutory lipids decreased substantially. Significant correlations between the SRA and the QoL scores were observed, the latter showing a substantial reduction at t2, ranking it as a reliable tool for monitoring disease evolution during TB treatment.DiscussionThese results suggest that evaluating a combination of these markers might be a valuable predictor of QoL improvement and a treatment response indicator; in particular, the oxidation metabolites and eicosanoid ratios could also be proposed as a future target for adjuvant therapies to reduce inflammation-associated lung injury in TB disease

Effectiveness and safety of the bevacizumab and erlotinib combination versus erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic review and meta-analysis

BackgroundThe EGFR gene encodes a protein that stimulates molecular pathways that allow the growth and development of the tumor microenvironment. The current preferred tyrosine kinase inhibitor (TKI) for the first-line treatment of EGFRm metastatic non-small cell lung cancer (NSCLC) is osimertinib. However, the combination of angiogenesis inhibitors and TKI has produced discordant results. We aimed to assess the effects of the bevacizumab and erlotinib combination in EGFRm metastatic NSCLC.MethodsUsing eligibility criteria focused on patients with EGFRm metastatic NSCLC treated with bevacizumab and erlotinib, we searched databases including clinical trial randomized studies and reviews published until April 15, 2023 in Medline (PubMed), Scopus, and Embase. Eight clinical trials (1,052 patients) were selected from 1,343 articles for quantitative and qualitative assessment. The risk of bias was assessed using the Cochrane Risk of Bias tool. Data were synthesized through random-effects meta-analysis.ResultsThe bevacizumab and erlotinib combination significantly improved the progression-free survival (PFS) (log(HR) = 0.63; 95% CI: 0.54–0.73, p &lt; 0.001) and overall response ratio (ORR) (RR = 0.79; 95% CI, 0.64–0.97, p = 0.03). However, it did not improve the overall survival (log(HR) = 0.93; 95% CI, 0.78–1.10, p = 0.38) and was associated with higher serious adverse events (SAEs) (OR = 3.48; 95% CI, 1.76–6.88, p = 0.005). A subgroup analysis suggested similar benefits in different mutation subtypes and brain metastasis condition. The evidence is limited by a moderate risk of bias across studies and heterogeneity in the reporting of SAEs.ConclusionsThe bevacizumab and erlotinib combination significantly improved PFS and ORR in EGFRm metastatic NSCLC but were also associated with higher-grade (≥3) adverse events. These results suggest that while the combination therapy may enhance progression-free survival and overall response, it does not improve the overall survival and is associated with higher toxicity. Thus, the treatment should be personalized based on individual patient comorbidities. Further prospective trials are needed to validate these results.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/#searchadvanced, identifier CDR 42022364692